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Abstract
Natural products produced by microorganisms have been an important source of new substances and lead compounds for the
pharmaceutical industry. Chromobacterium violaceum is a Gram-negative b-proteobacterium, abundant in water and soil in
tropical and subtropical regions and it produces violacein, a pigment that has shown great pharmaceutical potential. Crude
extracts of five Brazilian isolates of Chromobacterium sp (0.25, 2.5, 25, and 250 mg/mL) were evaluated in an in vitro antitumor
activity assay with nine human tumor cells. Secondary metabolic profiles were analyzed by liquid chromatography and
electrospray ionization mass spectrometry resulting in the identification of violacein in all extracts, whereas FK228 was
detected only in EtCE 308 and EtCE 592 extracts. AcCE and EtCE 310 extracts showed selectivity for NCI/ADR-RES cells in
the in vitro assay and were evaluated in vivo in the solid Ehrlich tumor model, resulting in 50.3 and 54.6% growth inhibition,
respectively. The crude extracts of Chromobacterium sp isolates showed potential and selective antitumor activities for certain
human tumor cells, making them a potential source of lead compounds. Furthermore, the results suggest that other
compounds, in addition to violacein, deoxyviolacein and FK228, may be involved in the antitumor effect observed.
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Introduction
Microorganisms have become an important source of
natural products of great interest to pharmaceutical
industries. Among current commercially available drugs,
approximately 63% are directly or indirectly derived from
natural products from microorganisms, plants and animals
(1). Chromobacterium violaceum is a Gram-negative
b-proteobacterium, facultative anaerobic, saprophyte,
free-living soil- and water-associated microorganism,
found in tropical and subtropical regions and it is abundant
in black waters and on the banks of Rio Negro, in
Amazonas, Brazil (2). The main characteristic of this
bacterium is the production of violacein, a purple pigment,
which exhibits activity against important tropical patho-
gens such as Mycobacterium tuberculosis, Trypanosoma
cruzi, Leishmania sp, and Plasmodium and is reported to
have bactericidal, cytotoxic, antiviral, antifungal, antioxi-
dant, antitumor (3), antiulcerogenic, immunomodulatory,
analgesic, antipyretic, and anti-diarrheal (4,5) activities.
Several studies have shown that violacein is also capable
of inducing apoptosis in a variety of cancer cell lines,
including leukemia lineages, suggesting a promising
clinical application to cancer treatment. The therapeutic
application of violacein to cancer chemoprevention has
been the focus of recent investigations (6,7). Violacein
has been shown to cause apoptosis in HL60 leukemic
cells but is ineffective in normal human lymphocytes and
monocytes (8). In all of the cases observed until now, the
toxicity to normal cells requires larger amounts of
violacein compared to cancer cells. The IC50 for cancer
cells is about 1-3 mM, as opposed to about 8-10 mM for
normal cells (3).
Moreover the antitumoral cyclic depsipeptide FK228
(romidepsin, formerly FR901228; NSC 630176) was
extracted from the C. violaceum WB968 strain. FK228 is
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a selective histone deacetylase inhibitor that has demon-
strated potent cytotoxic activity against the human tumor
cell lines A549 (lung), MCF7 (breast), SW480 (colon), and
PC-3 (prostate) and in vivo efficacy against both human
tumor xenografts and murine tumors. This metabolite has
shown a great therapeutic potential when compared to
trichostatin, a specific inhibitor of histone acetylation, and
is a selective agent against chronic leukemia of the
lymphocytic cells in clinical assays. Romidepsin was
approved by the US Food and Drug Administration in
2009 for use in patients with cutaneous T-cell lymphoma,
under the trade name Istodax, and offers a promising new
treatment for a disease with few existing therapies (9).
Thus, the aim of this study was to evaluate the
antitumor activity of crude extracts of Chromobacterium
sp isolates from Minas Gerais and Amazonas, Brazil, and
to establish a relationship between their differences in
secondary metabolite compositions. The crude extracts
showed cytotoxic activities with different potency and
selectivity toward human tumor cell lines presented in this
study. The presence or absence of compounds FK228
and violacein could not explain differences in antiprolif-
erative activity demonstrated by extracts suggesting that




Four isolates used in this study are preserved in the
Brazilian Collection of Industrial and Environmental
Microorganisms (CBMAI, CPQBA, UNICAMP, Campinas,
SP, Brazil). The isolates were recovered from water
samples in Rio Preto da Eva (CBMAI 308 and 310) and
Presidente Figueiredo (CBMAI 307) municipalities in
Amazonas, Brazil, and one of them (CBMAI 592) was
isolated from soil samples of Serra doCipo´ National Park, in
Minas Gerais, Brazil. C. violaceum-type strain (ATCC
12472T, USA; CBMAI 534T) was used as reference in
experiments.
Phylogenetic analysis of the 16S rRNA genes
Genomic DNA of Chromobacterium sp isolates was
used to amplify 16S rRNA gene with the bacterial primer
set 27f and 1401r (10). The sequencing was carried out
using the set of primers 28f (59-GAG TTT GAT CCT GGC
TCA G-39), 782r (59-ACC AGG GTA TCT AAT CCT GT-
39), 765f (59-ATT AGA TAC CCT GGT AG-39) and 1100r
(59-AGG GTT GGG GTG GTT G-39) according to
manufacturer instructions (Invitrogen, Brazil). Partial 16S
rRNA sequences obtained from isolates were assembled
in a contig using the phred/Phrap/CONSED program. The
sequences were aligned using the CLUSTAL X program
and analyzed with the MEGA software v.4. Evolutionary
distances were derived from sequence-pair dissimilarities
calculated as implemented in MEGA, using Kimura’s DNA
substitution model. The phylogenetic reconstruction was
done using the neighbor-joining algorithm with bootstrap
values calculated from 1000 replicate runs (10).
Crude extract preparation
Extracts derived from the metabolism of Chromo-
bacterium sp isolates were obtained after strain growth in
nutrient broth (Oxoid) medium at 30 ˚C for 48 h at
150 rpm. The bacterial suspension (40-60 g cells) was
centrifuged at 14.000 g for 10 min at 4 ˚C to recover cells.
Crude extracts of bacterial cells were obtained by
sequential extraction with chloroform, ethyl acetate and
ethanol solvents. The first crude extract obtained after 3 h
of extraction with 150 mL chloroform was designated as
chloroform crude extract (ClCE). The second crude
extract obtained after 6 h of extraction of the residue of
the ClCE extract with 150 mL ethyl acetate was denomi-
nated ethyl acetate crude extract (AcCE). The last one
was obtained with ethanol (150 mL) after 10 h of
extraction from the resulting residue of the AcCE extract
and was denominated ethanol crude extract (EtCE). The
crude extracts (ClCE, AcCE, and EtCE) were concen-
trated under vacuum at 40 ˚C (Bu¨chi Rotovapor R200 with
Bu¨chi heating steam bath B490, Switzerland), until
complete evaporation. The extracts were dissolved in
dimethylsulfoxide (DMSO) and assayed for in vitro
antitumor activity against human tumor cells. In addition,
AcCE 310 and EtCE 310 extracts were evaluated for
in vivo antitumor activity against a murine cancer model -
solid Ehrlich tumor.
HPLC analysis coupled with diode array detection
(DAD)
Crude extracts were analyzed for the presence of
violacein and deoxyviolacein by analytical HPLC-DAD
(control system SCL-10A VP, Shimadzu, Japan) using
a 3 mm Phenomenex Prodigy C18 column (150 mm 6
4.6 mm). Violacein and the crude extract from
Chromobacterium sp were diluted with 10 mL of the
mobile phase (H2O:acetonitrile 60:40, v/v) and filtered
with a 0.45-mm filter (Millipore, USA). Separation was
performed using isocratic mode H2O:acetonitrile (60:40,
v/v) at a flow rate of 1 mL/min, and injection of a 20-mL
volume. Absorbance was monitored at 230 and 575 nm.
Electrospray ionization mass spectrometry (ESI-MS)
Crude extracts were analyzed by ESI-MS to detect the
presence of the depsipeptide FK228. ESI-MS was
recorded on a Q-TOF mass spectrometer (Micromass,
UK) using direct infusion of a 10 mL/min methanol/H2O
(1:1) plus 0.1% formic acid solution and ionization by
electrospray in the positive ion mode with an ESI-QqTOF
configuration with an m/z resolution of ca. 6.000 and ca.
10-30 ppm accuracy (high resolution). Major operation
conditions were as follows: capillary voltage of 3.5 kV,
cone voltage of 35 V, source temperature of 100 ˚C,
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desolvation temperature of 80 ˚C and collision energy
of 70 eV. Continuous mass spectra were obtained by
scanning from 100 to 900 m/z. The MassLynx 4.1
software was used (Waters, USA)
In vitro antitumor activity assay
A panel of nine human cancer cell lines, i.e., MCF-7
(breast), NCI/ADR-RES (ovarian cancer with a phenotype
of multiple-drug resistance), UACC-62 (melanoma), NCI-
H460 (non-small cell lung), PC-3 (prostate), HT29 (colon),
OVCAR-3 (ovarian), 786-0 (renal), U251 (central nervous
system), and one normal VERO cell line (monkey kidney
normal cells) were used for in vitro antitumor activity
assay. Cancer cell lines were obtained from the National
Cancer Institute (NCI) at Frederick, USA and were grown
in RPMI-1640 medium (SigmaH, USA) supplemented with
5% fetal bovine serum (GibcoH, USA) at 37 ˚C with 5%
CO2. Cells were pricked when the cell monolayer reached
80% confluence in order to reach the ideal density to be
inoculated. The inoculation density for each cell line was
optimized by determining cell growth curves in a previous
study (11).
Cells on 96-well plates (100 mL cells/well) were treated
with 0.25, 2.5, 25, and 250 mg/mL extracts in DMSO/
RPMI at 37 ˚C, 5% CO2 in air for 48 h. The final DMSO
concentration (0.2%) did not affect cell viability. Cells were
then fixed with 50% TCA and cell proliferation was deter-
mined by spectrophotometric quantification (540 nm) of
cellular protein content using the sulforhodamine B assay
(12). With a concentration-response curve for each cell
line, TGI (concentration that produces total growth
inhibition or a cytostatic effect) was determined by
non-linear regression analysis (Table 1) using the Origin
7.5 software (OriginLab Corporation, USA). In the present
study, the TGI endpoint was used to compare crude
extract potency and specificity. A graphic representation
(Mean Graph) was constructed to show differential
cytotoxicity toward human tumor cell lines. The midline
of each portion represents the mean TGI endpoint,
calculated across nine cell lines. This mean value is then
subtracted from the value for each individual cell line and
plotted. More sensitive cell lines were visualized as bars
deflecting to the right, whereas more resistant cell lines
had bars extending to the left of the mean (Figure S1)
(13,14).
Antitumoral activity in a murine cancer model - solid
Ehrlich tumor (paws)
Adult male Swiss mice (25-35 g) obtained from
CEMIB (UNICAMP) were maintained under controlled
conditions of temperature (25 ± 2 ˚C) on a 12-h light/dark
cycle and 45-65% humidity with food and water ad libitum
for at least 7 days before the experiments. Studies were
carried out in accordance with current guidelines for the
veterinary care of laboratory animals (15) and with
the recommendations of the Bioethics Committee of the
Biology Institute (CEEA, UNICAMP, 1076-1).
Doxorubicin, as well as AcCE 310 and EtCE 310
extracts, were diluted in vehicle containing 1% Tween80
(Sigma-Aldrich) in saline (0.9% NaCl diluted in distilled
water). The tumor, derived from a spontaneous murine
mammary adenocarcinoma, was maintained in the ascitic
form by sequential passages in Swiss mice by weekly ip
transplantations of 5 6 105 tumor cells. The cells were
then diluted in 0.9% phosphate-buffered saline for a final
inoculation density of 2.5 6 106 cells?60 mL-1?animal-1
(16,17).
Experiments were designed according to Kleeb et al.







PC-3 OVCAR-3 HT29 VERO TGI
mean
value
AcCE 307 1.11 0.77 5.57 0.73 1.79 4.24 3.71 2.56 2.91 1.62 2.50 P
EtCE 307 5.74 6.33 22.84 9.00 7.76 7.33 12.75 5.96 23.18 9.81 11.07 M
AcCE 308 2.87 1.07 50.90 9.22 0.98 113.57 2.69 0.83 83.51 5.62 27.12 W
EtCE 308 101.47 58.68 327.30 58.98 46.75 219.58 89.35 66.96 234.80 58.65 126.25 I
AcCE 310 9.30 7.32 133.24 4.46 5.17 183.45 8.85 10.58 55.41 5.43 42.32 W
EtCE 310 12.66 7.53 118.79 5.03 5.46 150.85 9.65 13.18 9.44 6.99 33.95 W
AcCE 534 2.79 2.62 71.41 5.39 2.28 76.27 5.09 1.47 46.03 5.94 21.92 W
EtCE 534 40.25 45.92 165.06 54.63 41.08 238.25 41.53 40.27 55.80 105.64 82.84 I
AcCE 592 6.04 2.97 75.75 3.94 3.53 31.01 10.57 3.63 6.07 2.96 14.64 M
EtCE 592 92.98 35.47 250.00 29.26 37.55 74.68 89.54 60.76 29.97 32.74 73.29 I
Data are reported as total growth inhibition (TGI) in mg/mL (13). AcCE= ethyl acetate crude extract; EtCE= ethanol crude extract. U251
(central nervous system cancer), UACC-62 (melanoma), MCF-7 (breast cancer), NCI/ADR-RES (ovarian cancer expressing a multiple-
drug resistance phenotype), 786-0 (renal cancer), NCI-H460 (small cell lung carcinoma), PC-3 (prostate cancer), OVCAR-3 (ovarian
cancer), HT29 (colon cancer), and VERO (monkey kidney normal cells). Mean TGI value = inactive (I; TGI .50 mg/mL); weak activity
(W; 15 mg/mL , TGI , 50 mg/mL); moderate activity (M; 6.25 mg/mL , TGI , 15 mg/mL); potent activity (P; TGI , 6.25 mg/mL) (18).
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(16), with several modifications. The basal right hind paw
volume of male Swiss mice (n = 10/group) was
measured with a plethysmometer (Panlab, Spain) and
the animals were then inoculated with 2.5 6 106 viable
tumor cells in a volume of 60 mL injected into the right
hind footpad (16). Treatment started (ip) 24 h after cell
inoculation and was applied every 3 days for 15 days. The
doses used were 7.5 mg/kg for AtCE 310 and EtCE 310
and 5 mg/kg for doxorubicin (positive control). At the end
of the experiment, animals were sacrificed and both hind
paws were extracted and weighed. The weight differ-
ences, divided by body weight, were considered to be the
relative tumor weight. Results are reported as % inhibition
± SD. All results were submitted to one-way analysis of
variance (ANOVA), considering P # 0.05 to be a
significant difference between the control and treated
groups, followed by the Duncan test, using the StatSoftH
software (USA). Graphs were designed using the Origin
software (17).
Results and Discussion
The ethyl acetate and ethanol extracts of five
Chromobacterium sp isolates (CBMAI 307, 308, 310,
592, and 534T) showed significant antiproliferative acti-
vities in a dose-dependent manner. None of the crude
chloroform extracts showed significant activities and they
were considered to be inactive. According to Fouche et al
(18), four categories of extract activity were related to
the mean TGI value: inactive (TGI .50 mg/mL), weak
activity (15 mg/mL , TGI , 50 mg/mL), moderate activity
(6.25 mg/mL , TGI , 15 mg/mL) and potent activity
(TGI ,6.25 mg/mL). AcCE presented more activity than
EtCE. The most potent extract was AcCE 307 (mean TGI
value = 2.50 mg/mL) while EtCE 307 and AcCE 592
presented a moderate antiproliferative activity. On the
other hand, AcCE 308, AcCE 310, EtCE 310, and AcCE
534 showed a weak antiproliferative activity while EtCE
308, EtCE 534 and EtCE 592 were inactive.
Of all five Chromobacterium sp isolates, CBMAI 307
yielded the most active extract, i.e., AcCE 307. This
extract showed a selective antiproliferative effect against
NCI/ADR-RES (ovarian expressing phenotype multiple drug
resistance, TGI = 0.73 mg/mL), UACC-62 (melanoma,
TGI = 0.77 mg/mL), U251 (glioma, TGI = 1.11 mg/mL),
786-0 (renal, TGI = 1.79 mg/mL), and VERO (normal renal
cell line, TGI = 1.62 mg/mL; Table 1, Figure S1). The
difference in selectivity is reported in the mean graph of TGI
values (Figure S1). The mean graph was developed by the
NCI in order to emphasize the different effects of test
samples on various human tumor cell lines, and was
generated from a set of TGI values. Positive values project
to the right of the vertical line and represent cellular
sensitivities to the test extract that exceed the mean.
Negative values project to the left and represent cell line
sensitivities to the test extracts that are less than the
average value (13,14).
HPLC-UV analyses of crude extracts obtained from
Chromobacterium sp isolates were undertaken to estab-
lish a relationship of cytotoxic activity with the presence of
violacein, a pigment with reported antitumor activity (3-8).
No other compounds sensitive to UV detection in addition
to violacein and deoxyviolacein were detected at the
wavelengths measured (230 and 575 nm). HPLC-UV
analysis of the AcCE 307 extract demonstrated a 17:1
violacein/deoxyviolacein ratio (Figure S2).
Another important compound identified in C. viola-
ceum is FK228, which has been reported to show high
cytotoxicity for human tumor cell lines A549 (lung cancer),
MCF-7 (breast cancer), SW 480 (colon cancer), PC-3
(prostate cancer), and murine leukemia (3) in in vitro
evaluation. Since FK228 does not have a characteristic
UV spectrum and therefore is more difficult to detect by
UV, ESI-MS analysis was performed to detect the
presence of this compound in the extracts evaluated.
The presence of compound FK228 ions [M + H]+ at m/z
541.2, [M + Na]+ at m/z 563.2, or [M + K]+ at m/z 579.2
was monitored. Moreover, ESI-MS analysis confirmed
the HPLC-UV analysis by the detection of violacein ion
[M + H]+ at m/z 344.12 and deoxyviolacein [M + H]+ at m/z
328.11. In contrast, ESI-MS analysis of AcCE 307 did not
detect FK228 (data not shown).
On the other hand, EtCE 307 had a moderate anti-
proliferative activity (mean TGI value = 11.07 mg/mL)
with a very similar effect on U251 (TGI = 5.74 mg/mL),
OVCAR-3 (ovarian, TGI= 5.96 mg/mL), UACC-62 (TGI=
6.33 mg/mL), NCI-H460 (lung, TGI = 7.33 mg/mL), 786-0
(TGI = 7.76 mg/mL), NCI/ADR-RES (TGI = 9.00 mg/mL),
and VERO (normal renal cell line, TGI = 9.81 mg/mL) cell
lines (Table 1, Figure S1). HPLC-UV analysis of EtCE 307
at 575 and 230 nm revealed only the presence of
violacein with no detection of deoxyviolacein. Moreover
ESI-MS analysis of this extract detected the presence of
FK228.
Another extract that presented a moderate anti-
proliferative activity was AcCE 592 (mean TGI value =
14.64 mg/mL) with a selective effect on UACC-62 (TGI =
2.97 mg/mL), 786-0 (TGI = 3.53 mg/mL), OVCAR-3
(ovarian, TGI = 3.63 mg/mL), NCI/ADR-RES (TGI =
3.94 mg/mL), and VERO (normal renal cell line, TGI =
2.96 mg/mL) cell lines (Table 1). HPLC-UV analysis of
AcCE 592 demonstrated a 1:1 violacein/deoxyviolacein
ratio and the absence of FK228 by ESI-MS analysis
(Figure S2).
Among the extracts with weak antiproliferative activity,
AcCE 534, AcCE 308, AcCE 310, and EtCE 310
presented mean TGI values of 21.92 to 42.32 mg/mL.
AcCE 534 was selective for OVCAR-3 (TGI = 1.47 mg/
mL), 786-0 (TGI = 2.28 mg/mL), UACC-62 (TGI =
2.62 mg/mL), and U251 (TGI = 2.79 mg/mL) cell lines,
while AcCE 308 presented selectivity for OVCAR-3
(TGI = 0.83 mg/mL), 786-0 (TGI = 0.98 mg/mL),
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UACC-62 (TGI = 1.07 mg/mL), U251 (TGI = 2.87 mg/
mL), and PC-3 (prostate, TGI = 2.69 mg/mL). HPLC-UV
analysis of both AcCE 534 and AcCE 308 demonstrated a
similar violacein/deoxyviolacein proportion (13:1 and 15:1,
respectively), besides the absence of FK228 by ESI-MS
analysis (Figure S2).
On the other hand, both AcCE and EtCE 310
presented a similar selectivity for NCI/ADR-RES (TGI =
4.46 and 5.03 mg/mL, respectively), 786-0 (TGI = 5.17
and 5.46 mg/mL, respectively) and VERO (TGI = 5.43
and 6.99 mg/mL, respectively) cell lines (Table 1, Figure
S1). Also, both AcCE and EtCE 310 demonstrated a
similar violacein/deoxyviolacein proportion (20:1 and 34:1,
respectively) by HPLC-UV analysis, besides the absence
of FK228 by ESI-MS analysis (Figure S2).
These results suggest that the ratio of violacein/
deoxyviolacein alone does not explain the differences
observed in antiproliferative activity, as exemplified by the
potent antiproliferative activity presented by AcCE 307
while AcCE 534 presented just a weak antiproliferative
effect. Both extracts presented a similar violacein/deoxy-
violacein ratio (17:1 and 13:1, respectively; Figure S2).
Similarly, the presence or absence of compound
FK228 could not explain differences in antiproliferative
activity as demonstrated by EtCE 307, EtCE 308, and
EtCE 592. FK228 was identified in all of these extracts,
although EtCE 307 presented a potent antiproliferative
effect while EtCE 308 and EtCE 592 were inactive,
suggesting that other components are responsible for the
antiproliferative activity of EtCE 307.
Jensen et al. (19) reported associations between
secondary metabolite production and phylogenetically
distinct but closely related marine actinomycete species
belonging to the genus Salinispora. The pattern emerged
in a study that included global collection sites and this
indicates that secondary metabolite production can be a
species-specific phenotypic trait associated with broadly
distributed bacterial populations. The cytotoxic activities
with different potency and selectivity towards human
tumor cell lines presented in this study may be explained
by several secondary metabolites produced by the
isolates evaluated. In addition, this marked metabolic
diversity may be related to the great genetic diversity
presented by Brazilian Chromobacterium sp isolates. 16S
rRNA gene sequencing-based analysis of isolates
showed that CBMAI 307 and CBMAI 308 were closely
related to the strain types C. violaceum and C. pseudo-
violaceum, while the CBMAI 592 strain clustered with C.
piscinae and the CBMAI 310 strain may belong to a new
species of the genus, not yet described (data not shown).
Regarding the possibility of CBMAI 310 belonging to a
new species and the cytotoxicity observed for AcCE 310
and EtCE 310 extracts, both extracts had been evaluated
in an in vivo experimental model in order to confirm their
antitumor activity in a preliminary study. AcCE 310 and
EtCE 310 extracts (7.5 mg/kg, ip) resulted in a reduction
of tumor relative weight of 50.3 and 54.6% (P # 0.001),
respectively, compared to the control group (Figure 1).
These results indicated that both extracts were effective
in reducing tumor cell growth, confirming the antitumoral
activity of CBMAI 310 extracts, previously observed in
in vitro cytotoxicity assays. The systemic antitumor
activity was evaluated using the Ehrlich solid carcinoma
in mice, a rapidly growing tumor with very aggressive
behavior, able to grow in almost all mouse strains, which
suggests that the recognition of and the immune
responses to this tumor are independent of the major
histocompatibility complex, being controlled more by
innate immunity (inflammatory response) than by a T-cell
response (20).
The in vitro antiproliferative activity of extracts
obtained from Chromobacterium sp isolates presented
in this study suggests that compounds other than
violacein, deoxyviolacein and FK228 should also be
involved in distinct mechanisms of action. Furthermore,
the AcCE 310 and EtCE 310 extracts obtained from a new
candidate within the genus Chromobacterium, which
showed significant reduction in a murine cancer model





Figure 1. Effect of AcCE 310 and EtCE 310 on relative solid
tumor weight (difference of weights of healthy leg and leg
with tumor divided by body weight). Graph demonstrating relative
tumor weight after a 15-day experimental period. Treatments:
control group (vehicle, 10 mL/kg), doxorubicin (5 mg/kg), AcCE
310 and EtCE 310 extracts (7.5 mg/kg), given every 3 days, ip,
for 15 days. Data are reported as means ± SEM for 8 to 10
animals per experimental group. AcCE = acetate crude extract;
EtCE = ethanol crude extract. *P # 0.001 compared to control
(ANOVA followed by the Duncan test).
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